Anatomic Pathology Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product (Instruments, Consumables, and Services), By Application (Disease Diagnosis, Drug Discovery and Development, and Others), By End User (Hospitals, Research Laboratories, Diagnostic Laboratories and Others), and Region Forecast 2020-2031

Anatomic Pathology Market size was valued at US$ 18,935.2 million in 2024 and is projected to reach US$ 34,789.0 million by 2031 at a CAGR of 7.9% from 2025-2031. Moreover, the U.S. Global Anatomic Pathology Market is projected to grow significantly, reaching an estimated value of US$ 10,854.2 Million by 2031. Anatomic Pathology is a critical branch of pathology that focuses on the examination of tissues, organs, and whole bodies to diagnose diseases, including cancer, inflammatory disorders, and infections. It plays a vital role in personalized medicine and targeted therapies by providing precise diagnostic information. The market is experiencing robust growth, primarily driven by the rising global cancer burden, which necessitates accurate tissue diagnostics for early detection, disease staging, and personalized therapies.

Additionally, an aging population, advancements in digital pathology and AI, and expanding healthcare access in emerging markets further strengthen this demand. The key market trends include the digital transformation of pathology, AI-assisted diagnostics, remote consultations, and enhanced precision. The integration of AI and big data analytics is accelerating diagnostic turnaround times and reducing errors, particularly in oncology.A major opportunity lies in the growing adoption of digital pathology systems and AI tools, which improve pathologist productivity and address workforce shortages, while also supporting companion diagnostics in precision medicine.

However, despite these advances, the market faces several restraints, like high equipment costs, especially for digital scanners and automated processors, which create barriers for smaller laboratories. Additionally, workforce shortages, regulatory challenges, data interoperability issues, and limited reimbursement for advanced diagnostics continue to hamper market expansion. Addressing these challenges will be key to fully realizing the growth potential of the anatomic pathology sector.

Facts & Figures

• Personalized and Precision Medicine Demand: The rise of targeted therapies and personalized treatment protocols has increased the need for accurate, tissue-specific diagnostics and molecular profiling. For instance, PharmaNest presented digital pathology-based biomarkers for liver fibrosis and HCC, aiding in precision medicine. This reflects the growing use of anatomic pathology in guiding personalized treatment.
• Rising Global Cancer Prevalence: The increasing burden of cancer cases globally fuels demand for tissue-based diagnostics, especially for early detection, staging, and treatment planning. According to the WHO, global cancer cases reached 20 million in 2022 and are projected to surge to 35 million by 2050, a 77% increase. This dramatic rise necessitates expanded diagnostic infrastructure, including pathology services.
• Shortage of Skilled Pathologists: There is a growing global gap between the demand for pathology services and the number of trained pathologists, especially in developing regions. The Times (UK) highlighted that AI can help solve the global shortage of pathologists, citing that AI-assisted tools have boosted lab productivity by up to 40%, helping alleviate bottlenecks.
• Digital Pathology and AI Integration: The shift from glass slides to digital platforms, aided by AI, improves diagnostic speed, accuracy, remote access, and workflow efficiency.For instance, PathAI partnered with Northwestern Medicine to deploy its AISight® digital pathology platform across 11 hospitals, aiming to co-develop AI diagnostic tools that improve cancer detection accuracy and efficiency.
• Growing Investment and Partnerships in Pathology Technology: Rising venture capital and strategic partnerships are accelerating innovation, technology adoption, and scalability

Key Developments

• In June 2025, PathAI announced a multi-year collaboration with Northwestern Medicine to deploy its AISight® digital pathology platform across 11 hospitals. The partnership also includes co-development of AI diagnostics to improve efficiency and accuracy in cancer detection.
• In May 2025, PharmaNest presented five digital pathology biomarkers for liver fibrosis, inflammation, and HCC research at the International Liver Congress in Amsterdam.
• In March 2025, Proscia raised $50 million (bringing total funding to $130 million) to advance its Concentriq® AI digital pathology platform, which now supports over 22,000 patient diagnoses daily across major pharma collaborators.
• In January 2025, Deciphex secured €31 million to expand its AI-based platforms Diagnexia and Patholytix. These solutions support pathologists by digitizing slides and boosting diagnostic productivity by up to 40% in the UK and Ireland, with plans for North American expansion.

Anatomic Pathology Market Segmentation

Based on the product

• Instruments
• Consumables
• Services

The consumables represented the largest segment, which is due to their repetitive, high-volume usage in routine diagnostic procedures. It consists of reagents and antibodies, probes and kits, and other essential supplies. They aid in the staining, analysis, and molecular testing of tissue samples. In addition, they support the expansion of personalized medicine through companion diagnostics and molecular pathology. Unlike equipment (which is a one-time or infrequent investment), consumables are continuously required for every biopsy or tissue sample, creating a steady and recurring demand. The rise in cancer diagnostics, biopsy volumes, and molecular testing further increases consumable usage. This high turnover, coupled with clinical necessity in every test, drives their dominant market share.

Based on the application

• Disease Diagnosis
• Drug Discovery and Development
• Others

In the market, disease diagnosis holds the highest market share due to the rising incidence of cancer and chronic diseases that require tissue-based diagnostics for accurate detection and treatment planning. Hospitals, diagnostic labs, and research institutions heavily rely on anatomic pathology for early cancer detection, tumor staging, and prognostic evaluation. The increasing emphasis on precision medicine further amplifies the need for tissue diagnostics.

Additionally, the adoption of digital pathology and AI tools is enhancing diagnostic accuracy and workflow efficiency. In contrast, the "Others" segment, including forensic and academic uses, holds a relatively lower market share due to limited demand.

Based on the end user

• Hospitals
• Research Laboratories
• Diagnostic Laboratories
• Others

Among end users, hospitals hold the highest market share in the market. This dominance is driven by their high patient volumes, in-house pathology departments, and increasing cancer surgeries requiring tissue analysis for diagnosis and treatment planning. Pathologists in hospital settings handle a wide range of cases, from routine diagnostics to complex diseases, making hospitals the primary customer base for anatomic pathology services. Hospitals also benefit from greater funding for advanced diagnostic tools like digital pathology systems and AI integration. Their central role in disease diagnosis and patient care ensures consistent demand for anatomic pathology services.

On the other hand, the “Others” segment, which includes academic institutions and forensic labs, accounts for a smaller share due to limited clinical use and lower sample throughput.